Compare Effectiveness of Eplerenone vs Atenolol in Reversing the Remodelling Resistance Arteries in Subjects With HT

Pfizer

Status and phase: Completed; Phase 4

Conditions: Hypertension

Treatments: Drug: Eplerenone

Study type: Interventional

Funder types: Industry

Identifiers

NCT00147563

EPLA-0501-077

A6141016

Details and patient eligibility

About

To investigate the impact of antihypertensive therapy with the selective mineralocorticoid receptor blocker, eplerenone, on small resistance artery remodeling, compared to the effect of equivalent blood pressure control achieved with a b-blocker, atenolol.

Sex: All

Ages: 30 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pt with essential hypertension who have never been treated or untreated within the previous 6 months

Exclusion criteria

• History of Malignant Hypertension
• Sitting diastolic blood pressure > 115mmHg or sitting Systolic blood pressure > 200mmHg

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: Double Blind